Tech investors have poured billions into biotech, genomics, and AI diagnostics. Almost none of them have looked twice at the pharmacy counter. Christian Tadrus has spent his entire career behind it, and he's convinced that's exactly where the next wave of healthcare returns is hiding.

Watch The Full Episode Here:

"This is an industry that really is ripe for modernization, and that's what we're trying to do with our fund," Tadrus told host Connor Sattely on the Top Decile Podcast. His Pharmacy Innovator Fund, a $5M vehicle now live on Decile Access, backs startups transforming how American pharmacy actually works, from billing rails to clinical care delivery.

Tadrus's core insight is that pharmacy solved the wrong problem brilliantly. Over the last 40 years, the industry built "one of the most efficient models for putting pills in bottles fast, cheap and accurately," as he puts it. What it never built was the infrastructure to use the pharmacist standing next to those bottles.

"The pharmacist that's at the center of that patient care relationship is a highly trained healthcare professional," he explains. For more than two decades, pharmacy schools have trained graduates to operate as extended members of a patient's care team. "Yet, the industry has not really built the payment and the data access rails" to let them do it.

COVID exposed the gap. As the public woke up to what pharmacists could deliver, from immunizations to convenient frontline care, the industry realized, in Tadrus's words, "wait a second, we don't have the infrastructure in place to really capitalize on that knowledge." That mismatch between a trained workforce and missing rails is the entire investment thesis.

Tadrus isn't theorizing from a spreadsheet. He's a practicing community pharmacist who still works the counter at least one day a week. "I'm a frontline provider. I experience the inefficiency every day and I see the patient need," he says.

That frontline view led him into advocacy and policy work, including service on a state board of pharmacy and national standards organizations that shape how prescriptions move through the US system. Policy work led to advisory work, helping early pharmacy startups "understand what they don't know" and connecting them to subject matter experts across his network.

Then he noticed something. The companies he'd advised and invested in were outperforming. What they needed next wasn't more advice. It was capital. "I've got to bring some friends along with this ride," he recalls thinking. The fund was born from that realization: pharmacy innovation keeps dying in the pilot phase, and someone has to bridge the gap to scale. "Nobody ever bridges that gap to full scalability unless there's a very specific use case," he says. "That's where we're investing."

The fund moved quickly out of the gate. "We just launched less than 45 days ago. And we did our first close and we did our first investment within 48 hours," Tadrus says, with more deals in motion and a pipeline of companies entering diligence behind them.

The thesis centers on what he calls pharmacist enablement: platforms that let pharmacists bill and operate as providers on the medical side of the benefit, not just the siloed pharmacy benefit. His first investment went to a company doing exactly that, with software already used by thousands of pharmacies.

The fund is deliberately sized for this stage. "Our fund size is five million," he notes, focused on seed rounds where "our check sizes are gonna be $200,000 on average." The target isn't companies at scale. It's founders who've proven viability and hit a wall. "We're gonna make a big difference on somebody who is at capacity from their initial founders and they're strapped and they just need to grow."

And in this niche, access flows from expertise, not check size. "Money's pretty ubiquitous. The challenge is, do you find the right partners for that money and what can that partner bring?" Founders in pharmacy tech know the answer when the partner is one of the people who helped write the industry's operating rules.

Sattely noted on the episode that "new and emerging VCs have an edge because they're so close to the problems being solved." What makes Pharmacy Innovator Fund unusual is that its LPs are just as close. Tadrus is drawing exited founders and former CEOs from the pharmacy space, practicing pharmacists who want this future to exist, and even patients. Some tell him plainly: "I know this is messed up. I can help."

Many of these LPs are new to venture, and Tadrus takes the education seriously. He knows the reputation problem firsthand: in his industry, "venture capital tends to be vulturistic" is a common view. His answer is that the fund uses "the same mechanism, but it's being deployed in a way that has much more of a mission-driven approach and a less vulturistic approach to it."

The most disarming part of Tadrus's LP conversations is how he frames fund operations, borrowing the risk-mitigation mindset of his own profession. He walks investors through accreditation, KYC, and anti-money-laundering checks as features, not friction. "What happens if I get hit by a bus? I need to make sure that you guys are protected," he tells them.

The fund, he says, is "built from that mindset of doing it well, doing it right, and do it safely." Risk belongs in the portfolio, not the operations. And underneath the structure sits the same conviction that put him behind the counter in the first place: "At the core of anything we ever try and invest in, we really ought to be investing in something that helps people."

Learn more about the fund and request access on Decile Access: https://decileaccess.com/funds/pharmacy-innovator-fund

Pharmacy Innovator Fund is a $5M seed-stage venture fund investing in startups modernizing American pharmacy, with a focus on pharmacist enablement platforms that build the payment and data infrastructure for pharmacists to practice as providers. Christian Tadrus, PharmD, Founder and Investment Lead, is a practicing community pharmacist with decades of experience across pharmacy operations, regulation, and national standards work, and he pairs capital with deep subject matter expertise and an extensive industry network to help portfolio companies bridge the gap from pilot to scale.

Watch The Full Episode Here: https://www.youtube.com/watch?v=Zb8CBiQ9Q4I